Fig. 5

4A7 in combination with paclitaxel induces significant anti-proliferative and anti-survival effects on TNBC cells. A, MDA-MB-468 or HCC1806 cells were plated in 96-well plates. After 24 h, the culture medium was replaced with fresh medium containing indicated concentrations of paclitaxel with (Pac + 4A7) or without 4A7 (20 µg/ml), and incubated for additional 72 h. The percentages of surviving cells relative to controls, defined as 100% survival, were determined by MTS assays. Data shows a representative of three independent experiments. Bars, SD. *, p < 0.05, **, p < 0.01. B, MDA-MB-468 or HCC1806 cells were treated with vehicle (PBS), paclitaxel (2nmol/L), or combinations of 4A7 (20 or 40 µg/ml) and paclitaxel (2nmol/L) (Pac + 4A7) for 48 h. The cells were examined by western blot analyses of PARP (F-PARP, full length PARP; C-PARP, cleaved PARP), cleaved caspase-8 (C-caspase-8), cleaved caspase-3 (C-caspase-3), or β-actin. C, MDA-MB-468 or HCC1806 cells seeded in 6-well plates were treated with paclitaxel (4nmol/L) or combinations of 4A7 (20 µg/ml) and paclitaxel (4nmol/L) (Pac + 4A7) for 48 h. The cells were subjected to the LIVE/DEAD Cell Imaging assays. Dead cells were counted at three random fields. Bars, SD. ***, p < 0.0005